Lipoprotein (a) and the Occurrence of Lipid Disorders and Other Cardiovascular Risk Factors in Patients without Diagnosed Cardiovascular Disease
-
Published:2024-08-08
Issue:16
Volume:13
Page:4649
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Ratajczak Jakub1ORCID, Kubica Aldona1ORCID, Pietrzykowski Łukasz1ORCID, Michalski Piotr1ORCID, Kosobucka-Ozdoba Agata1ORCID, Buczkowski Krzysztof2ORCID, Krintus Magdalena3ORCID, Jankowski Piotr45ORCID, Kubica Jacek6ORCID
Affiliation:
1. Department of Cardiac Rehabilitation and Health Promotion, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland 2. Department of Family Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland 3. Department of Laboratory Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland 4. Department of Internal Medicine and Geriatric Cardiology, Center of Postgraduate Medical Education, 01-813 Warsaw, Poland 5. Department of Epidemiology and Health Promotion, School of Public Health, Center of Postgraduate Medical Education, 01-826 Warsaw, Poland 6. Department of Cardiology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland
Abstract
Background: Elevated lipoprotein (a) [Lp(a)] concentrations are linked mainly to genetic factors. The relationship between Lp(a) and other lipid disorders or cardiovascular (CV) risk factors has been less investigated. The aim of this study was to assess the occurrence of lipid disorders and other CV risk factors according to Lp(a) concentrations. Methods: A cross-sectional analysis of 200 primary-care patients who had not been diagnosed with CV disease was conducted. The following risk factors were assessed: older age, history of hypertension, diabetes mellitus or dyslipidemia, smoking, lack of physical activity, body mass index (BMI), and waist circumference. The following lipid parameters were measured: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and small, dense LDL (sdLDL-C). Patients were divided into two groups based on their Lp(a) concentrations: <30 mg/dL and ≥30 mg/dL. Results: In 70% of patients, the Lp(a) concentration was <30 mg/dL. The concentrations of lipid parameters did not differ between the groups. The rate of patients with sdLDL-C >1.0 mmol/L was higher in the low-Lp(a) group (10.0 vs. 1.7%, p = 0.04), with no significant differences regarding the other analyzed lipid disorders (p > 0.05). Both in the low- and high-Lp(a) group, most patients had two other abnormal lipid factors (45.0% and 60.0%, respectively). The distribution of impaired lipid parameters (p = 0.41) and other CV risk factors (p = 0.16) was similar in both groups. There was a lower rate of patients >60 years old (15.0% vs. 32.9%, p = 0.01) and with a BMI ≥ 25 kg/m2 (46.7% vs. 63.6%, p = 0.026) in the high-Lp(a) group, and previously diagnosed hyperlipidemia was more prevalent in this group (65.0% vs. 47.1%, p = 0.02). The occurrence of other cardiovascular risk factors did not differ significantly between the Lp(a) groups (p > 0.05). In the high-Lp(a) group, the highest proportion (25.0%) had two CV risk factors, and in the low-Lp(a) group, 31.4% had four CV risk factors. Conclusions: An elevated Lp(a) concentration is not related to the number of conventional CV risk factors or other impairment major lipid parameters.
Reference33 articles.
1. Management of Dyslipidemia in Poland: Interdisciplinary Expert Position Statement Endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot;Mickiewicz;Cardiol. J.,2022 2. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019;Roth;J. Am. Coll. Cardiol.,2020 3. Primary Prevention Efforts Are Poorly Developed in People at High Cardiovascular Risk: A Report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V Survey in 16 European Countries;Kotseva;Eur. J. Prev. Cardiol.,2021 4. Ratajczak, J., Kubica, A., Michalski, P., Pietrzykowski, Ł., Białczyk, A., Kosobucka-Ozdoba, A., Bergmann, K., Buczkowski, K., Krintus, M., and Jankowski, P. (2023). Determinants of Lipid Parameters in Patients without Diagnosed Cardiovascular Disease—Results of the Polish Arm of the EUROASPIRE V Survey. J. Clin. Med., 12. 5. Kubica, A., Pietrzykowski, Ł., Michalski, P., Kasprzak, M., Ratajczak, J., Siódmiak, J., Fabiszak, T., Buczkowski, K., Krintus, M., and Jankowski, P. (Cardiol. J., 2022). The Occurrence of Cardiovascular Risk Factors and Functioning in Chronic Illness in the Polish Population of EUROASPIRE V, Cardiol. J., ahead of print.
|
|